Proteolysis resistant active VEGF

US7491696B2 · kind B2 · utility

Assignee

• BAYER INNOVATION GMBH · DE

Inventors

• Sabine Eming · Cologne, DE
• Thomas Krieg · Erbach, DE
• Stephan Sollberg · Schwerin, DE
• Gereon Lauer · Radolfzell, DE

Key dates

• Filing date: Mar 6, 2003
• Grant date: Feb 17, 2009
• Expiry date: Mar 6, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.